WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

The 2026 WorkBoat Diesel Directory is here. See engine specs and manufacturer listings for the U.S. commercial fleet. → Download Free

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Charles River Laboratories International, Inc. Common Stock (NY:CRL)

235.11 +4.24 (+1.84%)
Streaming Delayed Price Updated: 12:10 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Charles River Laboratories International, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
These S&P500 stocks are moving in today's session ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday. 
Via Chartmill
News headline image
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Charles River Laboratories to Present at Jefferies Global Healthcare Conference
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
Drug Development Inputs & Services Stocks Q3 Teardown: Charles River Laboratories (NYSE:CRL) Vs The Rest
Looking back on drug development inputs & services stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
News headline image
5 Must-Read Analyst Questions From Charles River Laboratories’s Q3 Earnings Call
Charles River Laboratories’ third quarter results were met with negative market reaction, as investors focused on the company’s muted top-line growth and margin pressures. Management cited ongoing... 
Via StockStory
Topics Earnings
News headline image
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
3 Healthcare Stocks We Approach with Caution
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID... 
Via StockStory
Topics Stocks
News headline image
Corporate Earnings Fuel Market Gains, But Mixed Results Hint at Underlying Volatility
Recent third-quarter (Q3) 2025 corporate earnings have painted a complex yet largely positive picture for North American equity markets. While robust performances from key sectors, particularly... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
This Charles River Laboratories Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Robinhood To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
CRL Q3 Deep Dive: Portfolio Streamlining and End Market Stabilization Shape Outlook
Lab services company Charles River Laboratories (NYSE:CRL) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales were flat year on year at $1.00 billion. Its non-GAAP profit... 
Via StockStory
News headline image
Charles River (CRL) Q3 2025 Earnings Transcript ↗
Charles River (CRL) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Charles River Beat Expectations But Why Is The Stock Falling? ↗
Charles River stock dips as Q3 revenue slips, EPS beats estimates, and company raises 2025 outlook with cost cuts and $1 billion buyback plan. 
Via Benzinga
News headline image
Exploring the top movers within the S&P500 index during today's session. ↗
Curious about the S&P500 stocks that are in motion on Wednesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Why Charles River Laboratories (CRL) Shares Are Getting Obliterated Today
Shares of lab services company Charles River Laboratories (NYSE:CRL) fell 5.8% in the morning session after the company reported third-quarter results that revealed significant underlying weaknesses. 
Via StockStory
Topics Artificial Intelligence
News headline image
Wednesday's session: gap up and gap down stock in the S&P500 index ↗
Stay tuned for the market movements in the S&P500 index on Wednesday. Check out the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Charles River Laboratories (NYSE:CRL) Tops Q3 Earnings Estimates Despite Flat Revenue ↗
Charles River Labs Q3 earnings beat estimates with $2.43 EPS. The company raised its full-year EPS guidance while navigating a slight revenue decline. 
Via Chartmill
Topics Earnings
News headline image
Charles River Laboratories’s (NYSE:CRL) Q3: Beats On Revenue
Lab services company Charles River Laboratories (NYSE:CRL) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $1.00 billion. Its non-GAAP profit of $2.43 per share... 
Via StockStory
News headline image
Charles River Laboratories Provides Update on Strategic Review
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Announces Third-Quarter 2025 Results
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
What To Expect From Charles River Laboratories’s (CRL) Q3 Earnings
Lab services company Charles River Laboratories (NYSE:CRL) will be announcing earnings results this Wednesday before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Charles River Laboratories Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Discover which S&P500 stocks are making waves on Thursday. ↗
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday. 
Via Chartmill
News headline image
Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call
From Charles River Laboratories International, Inc.
Via Business Wire
News headline image
3 Reasons to Avoid CRL and 1 Stock to Buy Instead
The past six months have been a windfall for Charles River Laboratories’s shareholders. The company’s stock price has jumped 60.1%, hitting $170.64 per share. This was partly due to its solid quarterly... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.